SOHO 2022 | An insight into the optimal management of patients with DLBCL
In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the optimal management of patients with diffuse large B-cell lymphoma (DLBCL). Dr Westin explains how treatment approaches have changed over the years, and further highlights clinical trials and novel agents that have transformed the field. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, and ADC Therapeutics, and consulting with Kite/Gilead, BMS, Novartis, Genentech/Roche, Morphosys/Incyte, AstraZeneca, Janssen, Calithera, ADC Therapeutics, Merck, and MonteRosa.
